Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Scott

Showing results (301-310 of 360) with videos related to

Pageof 36
Sort By:
Molecular Cancer Therapeutics|March 4, 2015
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal AntibodyEdward B Reilly, Andrew C Phillips, Fritz G Buchanan, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Molecular Cancer Therapeutics|May 13, 2025
Characterization of mAb104, a Monoclonal Antibody Targeting a Conformationally Exposed, Tumor-specific epitope of HER2Sagun Parakh, Nhi Huynh, Diana Dong Cao, et al.
The Lancet. Oncology|May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranosticsAndrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology|January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastomaDavid A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Blood Advances|June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialEliza A Hawkes, Jodie Palmer, Richard Khor, et al.
The Journal of Biological Chemistry|April 13, 2004
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptorTerrance G Johns, Timothy E Adams, Jennifer R Cochran, et al.
Elife|July 21, 2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosisZeyad D Nassar, Chui Yan Mah, Jonas Dehairs, et al.
Pageof 36

Showing results (301-310 of 360) with videos related to

Sort By:
Pageof 36
Molecular Cancer Therapeutics|March 4, 2015
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal AntibodyEdward B Reilly, Andrew C Phillips, Fritz G Buchanan, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Molecular Cancer Therapeutics|May 13, 2025
Characterization of mAb104, a Monoclonal Antibody Targeting a Conformationally Exposed, Tumor-specific epitope of HER2Sagun Parakh, Nhi Huynh, Diana Dong Cao, et al.
The Lancet. Oncology|May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranosticsAndrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serumJennifer A Westwood, William K Murray, Melanie Trivett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Neuro-Oncology|January 1, 2017
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastomaDavid A Reardon, Andrew B Lassman, Martin van den Bent, et al.
Blood Advances|June 20, 2025
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trialEliza A Hawkes, Jodie Palmer, Richard Khor, et al.
The Journal of Biological Chemistry|April 13, 2004
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptorTerrance G Johns, Timothy E Adams, Jennifer R Cochran, et al.
Elife|July 21, 2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosisZeyad D Nassar, Chui Yan Mah, Jonas Dehairs, et al.
Pageof 36